Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.

ABSTRACT:

Purpose

We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.

Materials and methods

A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).

Results

The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progress

SUBMITTER: Kim HD 

PROVIDER: S-EPMC8291169 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature